Dr. Mellion brings deep knowledge in neuromuscular disorder investigation and procedure as a biopharma executive, researcher and doctor
BOSTON, April 05, 2022 (Globe NEWSWIRE) — PepGen, Inc., a business establishing the future generation of oligonucleotide therapeutics with the purpose of transforming the therapy of critical neuromuscular and neurologic diseases, now announced that it has appointed Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Progress. Dr. Mellion is double Board-qualified in neurology and scientific neurophysiology with more than two decades of medical enhancement experience and expended the first component of her occupation managing persons residing with muscular dystrophies ahead of transitioning to marketplace to focus on drug growth in neuromuscular and neurological indications.
“Michelle is a passionate, focused clinician with an impressive track file major clinical enhancement of neurology and neuromuscular condition therapies. As a working towards physician she has witnessed the effects that neuromuscular and neurodegenerative health conditions have on sufferers and their families,” stated James McArthur, Ph.D., President and Chief Government Officer of PepGen. “Her abilities in medical trial result actions and her posture as a considered leader in these indications will be crucial as we begin clinical trials of our guide candidates, PGN-EDO51 and PGN-EDODM1, and proceed our do the job to transform affected individual outcomes in this house.”
Dr. Mellion has comprehensive knowledge in evaluation and cure of neuromuscular and neurological indications, possessing worked in both of those educational and business configurations. Most recently, she served in roles of growing responsibility, together with Govt Healthcare Director, at Fulcrum Therapeutics where she led the design and style and implementation of Section I/II/III clinical trials for the company’s novel remedy of facioscapulohumeral muscular dystrophy. Though top clinical development initiatives at Fulcrum, she also worked as an Attending Medical doctor affiliated with Tufts Professional medical Centre, specializing in Neurology as a member of their Pediatrics department. Dr. Mellion has also held management roles at Vertex Prescription drugs and Biogen, in which she facilitated the preclinical translation and clinical progress of remedies for discomfort, a number of sclerosis and other indications. Prior to signing up for Biogen, Dr. Mellion was an Attending Neurologist in the Muscular Dystrophy Association (MDA) clinic and Attending Medical doctor and Assistant Professor of Neurology at Alpert Healthcare College, Brown University. Dr. Mellion finished her residency at Brown Healthcare School, obtained her M.D. from the Wake Forest College School of Medicine, and gained her B.A. in Molecular Biology from Colgate University.
“PepGen is strongly positioned to come to be a world leader in the treatment method of neuromuscular ailments, with a probable breakthrough remedy in Duchenne muscular dystrophy by now in scientific growth, and a differentiated therapeutic technique for myotonic dystrophy sort 1 that is swiftly approaching the clinic,” Dr. Mellion reported. “I am thrilled to be becoming a member of this dedicated, speedy-developing workforce, all of whom are committed to developing impactful therapeutics for a disease place that is pretty close to my coronary heart. I glimpse forward to doing the job with PepGen’s expert workforce to further the company’s preclinical and clinical-stage programs, and to supporting our mission to transform the life of those dwelling with scarce muscle mass illnesses and their communities.”
About PepGen
PepGen, Inc. is a biotechnology firm advancing up coming-generation oligonucleotide therapies for neuromuscular and neurologic conditions. PepGen’s proprietary Improved Delivery Oligonucleotides (EDOs) are created to focus on the underlying results in of exceptional illnesses, these types of as Duchenne muscular dystrophy (DMD) and myotonic dystrophy kind 1 (DM1), in a risk-free and effective method. In preclinical studies, PepGen’s increased delivery peptides demonstrated remarkably productive cell penetration and supply of therapeutic candidates to several tissue kinds, which includes cardiac tissue. PepGen was established by top neuromuscular and neurology researchers in Oxford and Cambridge, United kingdom, and is backed by a powerful syndicate of investors which includes RA Capital Administration, Oxford Science Enterprises, and other individuals. The enterprise is headquartered in Boston, Mass. For extra info, stop by www.pepgen.com or stick to PepGen on Twitter and LinkedIn.
Media Make contact with
Gwendolyn Schanker
LifeSci Communications
[email protected]
Trader Contact
Laurence Watts
Gilmartin Group
[email protected]
